The COVID-19 pandemic strained healthcare systems worldwide, delaying breast cancer screening and surgery. In 2019, approximately 80% of breast cancers in the U.S. were diagnosed on screening examinations, with 76.4% of eligible Medicare patients undergoing screening at least every two years. Since the start of the pandemic, many women have been reluctant to seek elective screening mammography, even with the lifting of pandemic-related restrictions in access to routine healthcare.
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Articles by Brian Diskin
Correction to: BTLA+CD200+ B cells dictate the divergent immune landscape and immunotherapeutic resistance in metastatic vs. primary pancreatic cancer | Oncogene
Correction to: Oncogene https://doi.org/10.1038/s41388-022-02425-4, published online 10 August 2022 The author Usman Asghar has been added in position 25 after being accidentally omitted from the published version. The original article has been corrected.
PD-L1 engagement on T cells promotes self-tolerance and suppression of neighboring macrophages and effector T cells in cancer
Abstract Programmed cell death protein 1 (PD-1) ligation delimits immunogenic responses in T cells. However, the consequences of programmed cell death 1 ligand 1 (PD-L1) ligation in T cells are uncertain. We found that T cell expression of PD-L1 in cancer was regulated by tumor antigen and sterile inflammatory cues.
SHP2 Inhibition Prevents Adaptive Resistance to MEK Inhibitors in Multiple Cancer Models
Research Briefs Carmine Fedele, Hao Ran, Brian Diskin, Wei Wei, Jayu Jen, Mitchell J. Geer, Kiyomi Araki, Ugur Ozerdem, Diane M. Simeone, George Miller, Benjamin G. Neel and Kwan Ho Tang DOI: 10.1158/2159-8290.CD-18-0444 Published October 2018 Abstract Adaptive resistance to MEK inhibitors (MEKi) typically occurs via induction of genes for different receptor tyrosine kinases (RTK) and/or their ligands, even in tumors of the same histotype, making combination strategies challenging.
SHP2 Inhibition Prevents Adaptive Resistance to MEK inhibitors in Multiple Cancer Models
SHP2 Inhibition Prevents Adaptive Resistance to MEK inhibitors in Multiple Cancer Models Carmine Fedele, Hao Ran, Brian Diskin, Wei Wei, Jayu Jen, Mitchell J Geer, Kiyomi Araki, Ugur Ozerdem, Diane M. Simeone, George Miller, Benjamin G Neel and Kwan Ho Tang Cancer Discov July 25 2018 DOI: 10.1158/2159-8290.CD-18-0444
Show More
loading
Actions
Is this you?
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.Get in touch with Brian
Contact Brian, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack